Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$24k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
6.8% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
2.0% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
8
users have liked this narrative
1
users have commented on this narrative
17
users have followed this narrative
8 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.9% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
8
users have liked this narrative
1
users have commented on this narrative
11
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
47.4% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Kura Oncology
AN
AnalystHighTarget
Consensus Narrative from 11 Analysts
Aging Populations And Precision Medicine Will Widen Oncology Frontiers
Key Takeaways Ziftomenib's potential best-in-class profile and streamlined trial strategy could drive rapid adoption and transform revenue and margin growth in AML. Expanding into solid tumors and chronic diseases diversifies revenue opportunities and positions Kura as a platform company with strong long-term growth prospects.
View narrative
US$40.00
FV
82.0% undervalued
intrinsic discount
158.86%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
DNA
Ginkgo Bioworks Holdings
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Automation And AI Expansion Will Advance Lab Markets Despite Risks
Key Takeaways Aggressive cost savings and early investments position Ginkgo for faster profitability, higher margins, and substantial operating leverage as growth areas expand. Commercialized automation platforms and entry into academic consumables market enable diversified, recurring revenue streams, while proprietary data assets unlock high-value AI partnerships.
View narrative
US$16.00
FV
25.4% undervalued
intrinsic discount
-4.16%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Navitas Semiconductor
AN
AnalystHighTarget
Consensus Narrative from 8 Analysts
Electrification And Renewables Will Unlock Vast GaN And SiC Potential
Key Takeaways Rapid adoption of advanced power technologies and innovative manufacturing positions Navitas for outsized market share gains, margin expansion, and accelerated revenue growth. Emerging opportunities in solid-state grid applications and U.S.-based manufacturing strengthen resilience, unlocking premium recurring sales and reducing supply chain risks.
View narrative
US$8.00
FV
19.6% undervalued
intrinsic discount
39.64%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
4 days ago
author updated this narrative
ASOS
AN
AnalystHighTarget
Consensus Narrative from 15 Analysts
Digital Commerce And AI Will Transform Ethical Fashion
Key Takeaways Accelerated adoption of Test & React and operational improvements are set to drive stronger gross margin, EBITDA, and cash flow growth than current forecasts anticipate. Innovations in AI personalization, digital marketing, and sustainability are unlocking higher customer engagement and positioning ASOS for increased market share and long-term revenue growth.
View narrative
UK£6.92
FV
55.6% undervalued
intrinsic discount
5.82%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Stitch Fix
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
AI-Driven Personalization Will Unlock Global Curated Apparel Markets
Key Takeaways Accelerated innovation in personalized shopping and proprietary AI positions Stitch Fix for rapid revenue growth, market share gains, and expanding client retention. Asset-light operations, sustainability trends, and a strong financial foundation fuel scalable, profitable expansion and resilience against market volatility.
View narrative
US$6.00
FV
13.2% undervalued
intrinsic discount
0.021%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
OrthoPediatrics
AN
AnalystHighTarget
Consensus Narrative from 7 Analysts
Global Population Growth And Healthcare Access Will Boost Pediatric Procedures
Key Takeaways Surging demand, rapid product adoption, and geographic expansion position OrthoPediatrics for revenue and margin growth well above current market expectations. Leadership in pediatric innovation and strengthening procedure volumes give the company enhanced pricing power and long-term earnings momentum.
View narrative
US$42.00
FV
54.5% undervalued
intrinsic discount
18.71%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Standard BioTools
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Advanced Multiomic Platforms Will Redefine Global Healthcare Standards
Key Takeaways Operational streamlining, strategic partnerships, and scientific leadership position Standard BioTools for robust, sustained expansion in revenue, margins, and market share. Ongoing adoption of precision medicine and multi-omic tools is expected to drive strong, recurring revenue growth from diverse global research and clinical markets.
View narrative
US$2.25
FV
43.6% undervalued
intrinsic discount
-24.81%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Definitive Healthcare
AN
AnalystHighTarget
Consensus Narrative from 8 Analysts
Secular AI And Digital Trends Will Unlock Healthcare Potential
Key Takeaways Expanding differentiated data, AI analytics, and seamless integrations position Definitive Healthcare for outpaced revenue growth, margin expansion, and leadership in a rapidly shifting healthcare landscape. Strong client retention, high-margin digital offerings, and solid cash flow enable strategic reinvestment and further market share gains beyond prevailing expectations.
View narrative
US$6.00
FV
36.8% undervalued
intrinsic discount
3.56%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Hippo Holdings
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
Digital Transformation And Climate Trends Will Boost US Home Insurance Appeal
Key Takeaways Strategic partnerships, technology adoption, and portfolio diversification position Hippo to outperform industry peers in growth, customer acquisition, and profitability. Proactive risk management and cost discipline support margin expansion, lowering earnings volatility and sustaining long-term profit growth despite increasing climate-related pressures.
View narrative
US$41.00
FV
24.2% undervalued
intrinsic discount
29.47%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Value any company in seconds
Popular companies